Asian Journal of Pediatric Research

Achondroplasia arises almost invariably from a single recurrent gain-of-function variant in the gene encoding fibroblast growth factor receptor 3, and has therefore become a reference case for genotype-directed drug development in paediatric rare disease. Within five years the field has moved from a single approved subcutaneous peptide analogue to a competitive landscape containing long-acting prodrugs of C-type natriuretic peptide, an orally administered pan-fibroblast growth factor receptor 1 to 3 tyrosine kinase inhibitor with pivotal placebo-controlled data, and receptor-selective inhibitors designed to spare the remaining receptor isoforms. This critical narrative review examines whether the evidence supporting these strategies has advanced at the same pace as the pharmacology. Literature was identified through structured searching of bibliographic and scholarly indexes, trial registries and institutional sources, complemented by citation tracking, and appraised for design adequacy, endpoint validity, consistency and translational reach rather than catalogued study by study. Three interpretive conclusions emerge. First, the mechanistic case for receptor-level inhibition is strong, yet the clinical case for isoform selectivity remains an inference from adult oncology dosing rather than a demonstrated paediatric advantage, because the doses used in skeletal dysplasia are far below those at which class toxicity is observed. Second, the apparent superiority of any single agent rests on indirect comparison across trials that differ in age range, baseline growth, imputation strategy and duration, and the differences in reported effect on annualised growth velocity are small relative to these design differences. Third, the endpoint on which the entire field depends is a one-year surrogate, and effects on body proportionality, foramen magnum development, functional capacity and adult stature remain inconsistent, exploratory or unmeasured. Selective inhibitors such as dabogratinib, and the oncology-developed compound vepugratinib, are best understood at present as pharmacological demonstrations that isoform-restricted inhibition is achievable, not as therapies of established paediatric benefit. Priorities include head-to-head or platform designs, growth-plate-relevant pharmacodynamic biomarkers, prospective imaging of the craniocervical junction, and outcome sets defined with affected families.